



ImmunoCellular
Investor Relations Department
23622 Calabasas Road
Suite 300
Calabasas, CA 91302
United States

Visit IR website [↗](#)

AMEX: IMUC


Last Trade:	0.35
Trade Time:	8:00 PM ET September 22, 2017
Change:	0.02 ↑ (7.165%)
Day Range	0.33 - 0.36
52-Week Range	0.25 - 4.92
Volume	1,375,150

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's pipeline includes: a Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells; ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; and ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer. ImmunoCellular recently announced the wind down of its phase 3 trial of ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- September 13, 2017*
[ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance](#)
- August 23, 2017*
[ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy](#)
- August 14, 2017*
[ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results](#)
- July 18, 2017*
[ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants](#)
- June 29, 2017*
[ImmunoCellular Therapeutics Receives Notice from NYSE MKT for Noncompliance with Continued Listing Standards](#)

Financials [\[View all \]](#)

- March 9, 2017*
[Annual Report \(10-K\)](#)
- April 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- August 14, 2017*
[Quarterly Report \(10-Q\)](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)
- November 10, 2016*
[Quarterly Report \(10-Q\)](#)